Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07067112 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Suppressive Functions of Regulatory T Cells in Migraine

Study acronym: SIIM-reg
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Start date changed from estimate of Jul 1, 2026 to Sep 10, 2026
    • Eligibility criteria shortened, about 29 words
    • Site details revised
    • Publications: details revised at 19 of 19 entries
  2. Notable Start date: Jan 1, 2026 to Jul 1, 2026v5
  3. Minor Study description shortened, about 11 wordsv4
  4. Notable Start date: Oct 1, 2025 to Jan 1, 2026
    • Secondary endpoints: 2 to 3
    • Study description expanded, about 4 words
    v3
  5. Minor Study description expanded, about 7 wordsv2
  6. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and/or inflammatory diseases. Cytokine and immune cell dysregulations have been evidenced in migraine. Inflammation seems to play an important role in migraine chronification; however, the inflammatory mechanisms involved in migraine pathophysiology remain unclear. Regulatory T (Treg) cells play a central role in maintaining immune homeostasis. They regulate effector T (Teff) cell proliferation and cytokine production, through several suppressive mechanisms, such as the hydrolysis of adenosine triphosphate (ATP) into adenosine (ADO), mediated by surface enzymes Cluster Differentiation 39 (CD39) and Cluster Differentiation 73 (CD73). ATP is involved in pain processes in migraine, and insufficient hydrolysis could participate in pain chronification. Recent studies suggest altered proportions of Treg cells in migraine, and decreased levels of CD39-positive (CD39+) Treg cells, suggesting Treg suppressive functions may be decreased in the disease. However, there have been no functional studies to date to confirm this hypothesis. The investigators believe Treg suppressive functions may be decreased in migraine, and that such alterations may be caused by a malfunction in the ADO pathway.
Trial Details
NCT Number NCT07067112
Lead Sponsor University Hospital, Clermont-Ferrand
Conditions
(from sponsor)
Chronic Migraine
Related terms Inflammation, Migraine Disorders
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov